NASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis $59.02 -0.95 (-1.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$59.02 0.00 (0.00%) As of 08/1/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Halozyme Therapeutics Stock (NASDAQ:HALO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Halozyme Therapeutics alerts:Sign Up Key Stats Today's Range$58.53▼$60.2750-Day Range$52.02▼$60.0852-Week Range$42.01▼$70.50Volume1.68 million shsAverage Volume1.28 million shsMarket Capitalization$7.27 billionP/E Ratio15.70Dividend YieldN/APrice Target$62.70Consensus RatingHold Company Overview Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. Read More Halozyme Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreHALO MarketRank™: Halozyme Therapeutics scored higher than 95% of companies evaluated by MarketBeat, and ranked 59th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingHalozyme Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 4 buy ratings, 6 hold ratings, and 2 sell ratings.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Halozyme Therapeutics' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth31.50% Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 31.50% in the coming year, from $4.73 to $6.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 15.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 15.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.40. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 20.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Halozyme Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.88% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Halozyme Therapeutics has recently decreased by 5.70%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.12 Percentage of Shares Shorted7.88% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Halozyme Therapeutics has recently decreased by 5.70%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment1.14 News SentimentHalozyme Therapeutics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Halozyme Therapeutics this week, compared to 12 articles on an average week.Search InterestOnly 1 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,262,400.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Halozyme Therapeutics' insider trading history. Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Stock News HeadlinesInsider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells 20,000 Shares of StockJuly 11, 2025 | insidertrades.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of "Hold" from BrokeragesAugust 1 at 2:19 AM | americanbankingnews.comThis Crypto Is Set to Explode in JanuaryThis Could Be the Most Important Crypto Law in History While the world celebrates Bitcoin becoming 2025’s top-performing asset, smart hedge funds are accumulating elsewhere. During the upcoming Crypto Hedge Fund Summit, you'll discover exactly which coins they’ve loaded up on before this historic vote. | Crypto 101 Media (Ad)Halozyme Therapeutics Sees Its Composite Rating Rise To 96July 31 at 6:19 PM | msn.comMorgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PTJuly 28, 2025 | finance.yahoo.com10 Most Profitable Biotech Stocks to Invest in NowJuly 27, 2025 | insidermonkey.comHalozyme Therapeutics, Inc.: European Commission Approved DARZALEX Faspro for Adult Patients with Smouldering Multiple MyelomaJuly 24, 2025 | finanznachrichten.deJ&J says Darzalex injectable granted EU nod for smouldering multiple myelomaJuly 24, 2025 | msn.comSee More Headlines HALO Stock Analysis - Frequently Asked Questions How have HALO shares performed this year? Halozyme Therapeutics' stock was trading at $47.81 on January 1st, 2025. Since then, HALO shares have increased by 23.4% and is now trading at $59.02. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings data on Tuesday, May, 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. The business's revenue was up 35.2% compared to the same quarter last year. Read the conference call transcript. Does Halozyme Therapeutics have any subsidiaries? Halozyme Therapeutics subsidiaries include Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Who are Halozyme Therapeutics' major shareholders? Top institutional investors of Halozyme Therapeutics include Congress Asset Management Co. (1.49%), Stephens Investment Management Group LLC (1.05%), TD Asset Management Inc (0.89%) and Boston Trust Walden Corp (0.69%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Jeffrey William Henderson, James M Daly and Nicole Labrosse. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and NVIDIA (NVDA). Company Calendar Last Earnings5/06/2025Today8/02/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees390Year Founded1998Price Target and Rating Average Price Target for Halozyme Therapeutics$62.70 High Price Target$75.00 Low Price Target$47.00 Potential Upside/Downside+6.2%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$3.76 Trailing P/E Ratio15.70 Forward P/E Ratio12.48 P/E Growth0.4Net Income$444.09 million Net Margins44.76% Pretax Margin55.79% Return on Equity136.91% Return on Assets26.05% Debt Debt-to-Equity Ratio3.13 Current Ratio8.39 Quick Ratio7.30 Sales & Book Value Annual Sales$1.02 billion Price / Sales7.16 Cash Flow$4.58 per share Price / Cash Flow12.89 Book Value$2.86 per share Price / Book20.64Miscellaneous Outstanding Shares123,220,000Free Float120,264,000Market Cap$7.27 billion OptionableOptionable Beta1.17 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:HALO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.